OrganoClick (ORGC) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
Net sales for Q3 2024 were SEK 28.9 million, down 13.7% year-over-year, with EBIT at SEK -3.0 million, reflecting continued challenges in industrial segments but strong growth in consumer brands.
For the first nine months, net sales declined 10.3% to SEK 105.8 million, with EBIT at SEK -3.0 million, and improved cash flow from operating activities at SEK -1.1 million.
Green coatings & maintenance products saw robust 24% sales growth in Q3, while Nonwoven & fiber technologies and Functional wood segments faced double-digit declines.
Financial highlights
Q3 gross margin was 23.0% (23.8% last year); EBIT margin was -10.4% (-8.4%).
Earnings per share for Q3 were SEK -0.05 (-0.04); for Jan–Sep, SEK -0.10 (-0.08).
Cash and cash equivalents at period end were SEK 4.3 million, with a quick ratio of 34.3%.
Net debt/equity ratio increased to 147.3% from 100.8% a year earlier.
Outlook and guidance
Consumer brands are expected to continue growing in 2025, with positive developments in export markets and new customer gains.
Industrial segments, especially Nonwoven & fiber technologies, are likely to remain challenged due to weak restaurant and construction markets.
The company prioritizes returning to sales growth and profitability in 2025.
Latest events from OrganoClick
- Improved margins and cost reductions offset lower sales, but major customer loss will impact future growth.ORGC
Q2 2026 - Returned to operating profit with improved margins, but faces future sales risk from key customer loss.ORGC
Q1 2026 - Sales fell sharply and losses deepened, but cost cuts aim to restore profitability in 2026.ORGC
Q4 2025 - Sales fell 22% in Q3, but cost cuts and new financing target improved 2026 results.ORGC
Q3 2025 - Q2 2025 sales dropped 22.7% year-over-year, with losses widening and new funding secured.ORGC
Q2 2025 - Strong growth in sustainable chemicals, positive cash flow, and European expansion drive 2025 outlook.ORGC
ABGSC Investor Days - Gross margin rose to 29.1% as EBIT neared breakeven despite a 5.6% sales decline.ORGC
Q2 2024 - Biobased innovation drives OrganoClick's growth and expansion in European markets.ORGC
ABGSC Investor Days - Sales fell 7.3% as industrial headwinds persisted, but consumer brands expanded retail reach.ORGC
Q1 2025